Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron

被引：146

作者：

Bell, G. C. ^{[1
]}

Caudle, K. E. ^{[2
]}

Whirl-Carrillo, M. ^{[3
]}

Gordon, R. J. ^{[4
]}

Hikino, K. ^{[5
]}

Prows, C. A. ^{[6
]}

Gaedigk, A. ^{[7
]}

Agundez, J. A. G. ^{[8
,9
]}

Sadhasivam, S. ^{[10
,11
]}

Klein, T. E. ^{[3
]}

Schwab, M. ^{[12
,13
,14
,15
]}

机构：

[1] Mission Hlth, Personalized Med Program, Asheville, NC USA

[2] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA

[3] Stanford Univ, Dept Genet, Stanford, CA 94305 USA

[4] Univ Calif San Diego, Dept Anesthesiol, San Diego, CA 92103 USA

[5] Univ Chicago, Comm Clin Pharmacol & Pharmacogen, Chicago, IL 60637 USA

[6] Cincinnati Childrens Hosp Med Ctr, Div Patient Serv, Div Human Genet, Cincinnati, OH 45229 USA

[7] Childrens Mercy Kansas City, Div Clin Pharmacol Toxicol & Therapeut Innovat, Kansas City, MO USA

[8] Univ Missouri, Dept Pediat, Kansas City, MO 64110 USA

[9] Univ Extremadura, Dept Pharmacol, Caceres, Spain

[10] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA

[11] Cincinnati Childrens Hosp Med Ctr, Dept Anesthesia, Cincinnati, OH USA

[12] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany

[13] Univ Tubingen, Tubingen, Germany

[14] Univ Hosp Tubingen, Dept Clin Pharmacol, Tubingen, Germany

[15] Univ Tubingen, Dept Pharm & Biochem, Tubingen, Germany

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 102卷 / 02期

基金：

美国国家卫生研究院;

关键词：

TYPE-3 RECEPTOR ANTAGONISTS; CHEMOTHERAPY-INDUCED NAUSEA; IN-VITRO METABOLISM; POSTOPERATIVE NAUSEA; ABCB1; POLYMORPHISMS; CYTOCHROME-P450; GRANISETRON; EFFICACY; THERAPY; PHARMACOKINETICS;

D O I：

10.1002/cpt.598

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are used in the prevention of chemotherapy-induced, radiation-induced, and postoperative nausea and vomiting. CYP2D6 polymorphisms can influence the metabolism of some of these drugs (i.e., ondansetron and tropisetron), thereby affecting drug efficacy. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for ondansetron and tropisetron based on CYP2D6 genotype (updates at www.pharmgkb.org and cpicpgx.org).

引用

页码：213 / 218

页数：6

共 50 条

[1] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy
Goetz, Matthew P.
Sangkuhl, Katrin
Guchelaar, Henk-Jan
Schwab, Matthias
Province, Michael
Whirl-Carrillo, Michelle
Symmans, W. Fraser
McLeod, Howard L.
Ratain, Mark J.
Zembutsu, Hitoshi
Gaedigk, Andrea
van Schaik, Ron H.
Ingle, James N.
Caudle, Kelly E.
Klein, Teri E.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (05) : 770 - 777
[2] Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update
Hicks, J. K.
Sangkuhl, K.
Swen, J. J.
Ellingrod, V. L.
Muller, D. J.
Shimoda, K.
Bishop, J. R.
Kharasch, E. D.
Skaar, T. C.
Gaedigk, A.
Dunnenberger, H. M.
Klein, T. E.
Caudle, K. E.
Stingl, J. C.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (01) : 37 - 44
[3] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
Hicks, J. K.
Bishop, J. R.
Sangkuhl, K.
Mueller, D. J.
Ji, Y.
Leckband, S. G.
Leeder, J. S.
Graham, R. L.
Chiulli, D. L.
LLerena, A.
Skaar, T. C.
Scott, S. A.
Stingl, J. C.
Klein, T. E.
Caudle, K. E.
Gaedigk, A.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (02) : 127 - 134
[4] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype
Crews, K. R.
Gaedigk, A.
Dunnenberger, H. M.
Klein, T. E.
Shen, D. D.
Callaghan, J. T.
Kharasch, E. D.
Skaar, T. C.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (02) : 321 - 326
[5] Considerations for the Utility of the CPIC Guideline for CYP2D6 Genotype and Codeine Therapy
Crews, Kristine R.
Caudle, Kelly E.
Dunnenberger, Henry M.
Sadhasivam, Senthilkumar
Skaar, Todd C.
[J]. CLINICAL CHEMISTRY, 2015, 61 (05) : 775 - 776
[6] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy
Desta, Zeruesenay
Gammal, Roseann S.
Gong, Li
Whirl-Carrillo, Michelle
Gaur, Aditya H.
Sukasem, Chonlaphat
Hockings, Jennifer
Myers, Alan
Swart, Marelize
Tyndale, Rachel F.
Masimirembwa, Collen
Iwuchukwu, Otito F.
Chirwa, Sanika
Lennox, Jeffrey
Gaedigk, Andrea
Klein, Teri E.
Haas, David W.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 106 (04) : 726 - 733
[7] Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy
Robinson, Katherine M.
Eum, Seenae
Desta, Zeruesenay
Tyndale, Rachel F.
Gaedigk, Andrea
Crist, Richard C.
Haidar, Cyrine E.
Myers, Alan L.
Samer, Caroline F.
Somogyi, Andrew A.
Zubiaur, Pablo
Iwuchukwu, Otito F.
Whirl-Carrillo, Michelle
Klein, Teri E.
Caudle, Kelly E.
Donnelly, Roseann S.
Kharasch, Evan D.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024,
[8] Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants
Hicks, J. K.
Swen, J. J.
Thorn, C. F.
Sangkuhl, K.
Kharasch, E. D.
Ellingrod, V. L.
Skaar, T. C.
Mueller, D. J.
Gaedigk, A.
Stingl, J. C.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (05) : 402 - 408
[9] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
Amstutz, Ursula
Henricks, Linda M.
Offer, Steven M.
Barbarino, Julia
Schellens, Jan H. M.
Swen, Jesse J.
Klein, Teri E.
McLeod, Howard L.
Caudle, Kelly E.
Diasio, Robert B.
Schwab, Matthias
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (02) : 210 - 216
[10] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing
Birdwell, K. A.
Decker, B.
Barbarino, J. M.
Peterson, J. F.
Stein, C. M.
Sadee, W.
Wang, D.
Vinks, A. A.
He, Y.
Swen, J. J.
Leeder, J. S.
van Schaik, R. H. N.
Thummel, K. E.
Klein, T. E.
Caudle, K. E.
MacPhee, I. A. M.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (01) : 19 - 24

← 1 2 3 4 5 →